


Researchers complete phase one human trials of smart pills

April 24 2017





Phase one human trials of smart pills that could revolutionise the prevention and diagnosis of gut disorders and diseases have been completed by researchers in Melbourne, Australia Credit: RMIT University



Researchers at RMIT University in Melbourne, Australia, have successfully completed phase one human trials of ingestible capsules that have the potential to revolutionise the prevention and diagnosis of gut disorders and diseases.

The research team, led by the pills' co-inventor Distinguished Professor Kourosh Kalantar-zadeh, tested the ingestible smart capsules (the size of a vitamin pill) that journey through and measure gas levels in the gastrointestinal tract.

One in five people will suffer from a gastrointestinal disorder in their lifetime, with 30 per cent of patients remaining undiagnosed. RMIT is one of the leading universities in the world researching the development of ingestible sensors.

The ingestible technology has demonstrated several thousand -times more sensitivity to gut gases than alternative techniques.

"Currently, one of the only methods for diagnosing gut disorders, such as mal-absorption of carbohydrates, <u>irritable bowel syndrome</u> and inflammable bowel disease, is to measure hydrogen concentrations in the breath," Kalantar-zadeh said.

"However, breath tests are mired by a lack of sensitivity and specificity and are unable to provide the necessary gold standard for diagnosis."

Co-inventor Dr Kyle Berean said: "Ingestible sensors also offer a reliable diagnostic tool for colon cancer, meaning that people won't have to undergo colonoscopies in future."





Distinguished Professor Kourosh Kalantar-zadeh, leader of the research team behind the ingestible smart capsules. Credit: RMIT University

A key finding from the initial trials was just how safe the new technology is.

"Smart pills are harmless and there is no risk of <u>capsule</u> retention," Berean said.

An added advantage is that the capsules can be synched with smartphones, meaning results are easily accessible by users and doctors online.

The potential applications from this technology are profound.



"The sensors allow us to measure all the fluids and gases in the gut giving us a multidimensional picture of the human body," Kalantar-zadeh said. "Gas sensing is just the beginning."

The human trials were undertaken with colleagues from Monash University, who Kalantar-zadeh was quick to praise.

"We have been lucky to have Monash medical academics helping us on this journey," he said. "Without their input we would not be able to proceed."

More information: Kourosh Kalantar-zadeh et al, Ingestible Sensors, *ACS Sensors* (2017). DOI: 10.1021/acssensors.7b00045

Provided by RMIT University

Citation: Researchers complete phase one human trials of smart pills (2017, April 24) retrieved 23 June 2024 from https://phys.org/news/2017-04-phase-human-trials-smart-pills.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.